Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -970.11% is in line with its 5-year average of -938.97%, around the middle of its 5-year range (-1747.64%–-21.74%).
17.40% above its 12-month average of -1174.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1475.08%.
EBITDA MARGIN
-970.11%
EBITDA MARGIN AVG TTM
-1174.48%
EBITDA MARGIN AVG 3Y
-901.27%
EBITDA MARGIN AVG 5Y
-938.97%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+17.40%
CURRENT VS 3Y AVG
-7.64%
CURRENT VS 5Y AVG
-3.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aclaris Therapeutics, Inc.
Market Cap
$513.77M
EBITDA Margin
-970.11%
TTM Avg
-1174.48%
3Y Avg
-901.27%
5Y Avg
-938.97%
Market Cap
$512.70M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$516.91M
EBITDA Margin
-230187.80%
TTM Avg
-372428.90%
3Y Avg
-255754.79%
5Y Avg
-154022.75%
Market Cap
$504.23M
EBITDA Margin
-1406.75%
TTM Avg
-1406.75%
3Y Avg
-151851.64%
5Y Avg
-92301.39%
Market Cap
$504.84M
EBITDA Margin
-35.08%
TTM Avg
-77.94%
3Y Avg
-77.08%
5Y Avg
-62.83%
Market Cap
$502.20M
EBITDA Margin
-1179818.18%
TTM Avg
-754929.09%
3Y Avg
-428982.67%
5Y Avg
-428982.67%
Market Cap
$499.60M
EBITDA Margin
10.90%
TTM Avg
10.39%
3Y Avg
7.60%
5Y Avg
5.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $513.77M | -970.11% | -1174.48% | -901.27% | -938.97% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $512.70M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.91M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.23M | -1406.75% | -1406.75% | -151851.64% | -92301.39% |
| 908 Devices Inc. (MASS)vs › | $504.84M | -35.08% | -77.94% | -77.08% | -62.83% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $502.20M | -1179818.18% | -754929.09% | -428982.67% | -428982.67% |
| Immix Biopharma, Inc. (IMMX)vs › | $528.58M | N/A | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.60M | 10.90% | 10.39% | 7.60% | 5.15% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $527.68M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $528.51M | 1.18% | -15.78% | -775.36% | -845.24% |
Gross Margin
73.3%
EBITDA Margin
-970.1%
Operating Margin
-975.9%
Net Margin
-921.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1475.08% |
| 2026-03-31 | -1106.71% |
| 2025-12-31 | -1747.64% |
| 2025-09-30 | -513.46% |
| 2025-06-30 | -1029.49% |
| 2025-03-31 | -1234.09% |
| 2024-12-31 | -1080.58% |
| 2024-09-30 | -236.82% |
| 2024-06-30 | -463.20% |
| 2024-03-31 | -779.32% |
| 2023-12-31 | -21.74% |
| 2023-09-30 | -337.84% |
| 2023-06-30 | -1690.58% |
| 2023-03-31 | -1175.63% |
| 2022-12-31 | -372.62% |
| 2022-09-30 | -108.74% |
| 2022-06-30 | -1360.47% |
| 2022-03-31 | -1286.92% |
| 2021-12-31 | -1512.06% |
| 2021-09-30 | -1211.81% |
| 2021-06-30 | -973.63% |
| 2021-03-31 | -1589.25% |
| 2020-12-31 | -858.23% |
| 2020-09-30 | -681.44% |
| 2020-06-30 | -526.64% |
| 2020-03-31 | -1061.12% |
| 2019-12-31 | -1573.79% |
| 2019-09-30 | -2159.92% |
| 2019-06-30 | -810.91% |
| 2019-03-31 | -696.47% |
| 2018-12-31 | -1037.88% |
| 2018-09-30 | -2031.08% |
| 2018-06-30 | -861.34% |
| 2018-03-31 | -2748.30% |
| 2017-12-31 | -2528.63% |
| 2017-09-30 | -2725.15% |
